Biofrontera Aktie
WKN: 604611 / ISIN: DE0006046113
13.08.2025 23:50:55
|
Biofrontera Revenue Jumps 15% in Q2
Biofrontera (NASDAQ:BFRI), a specialty biopharmaceutical company focused on dermatology solutions, released its financial results for the second quarter of fiscal 2025 on August 13, 2025. The headline news was a jump in revenue—totaling $9.0 million (GAAP)—which outpaced analyst expectations of $8.3 million, resulting in an 8.4% beat. Sales were driven by higher demand and improved pricing for Ameluz®, its main product. Despite the revenue growth and evidence of commercial progress, the bottom line moved in the opposite direction. Biofrontera posted a net loss per share of $(0.57) (GAAP), missing the consensus estimate of $(0.42). The wider loss was largely the result of a significant increase in legal expenses. Overall, the quarter showed top-line momentum but highlighted ongoing challenges with profitability and cost control. Source: Analyst estimates for the quarter provided by FactSet. Biofrontera develops and markets dermatological drugs and medical devices to treat skin conditions, with a main focus on actinic keratosis—a type of pre-cancerous skin lesion. Its principal product, Ameluz®, is a prescription medicine used with the company’s RhodoLED® photodynamic therapy (PDT) lamps for skin treatments.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Q2 Holdings Incmehr Nachrichten
29.07.25 |
Ausblick: Q2 veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) | |
06.05.25 |
Ausblick: Q2 legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) |
Analysen zu Q2 Holdings Incmehr Analysen
Aktien in diesem Artikel
Q2 Holdings Inc | 57,00 | 0,00% |
|